购物车
您的购物车当前为空
别名 瑞卡西单抗, SHR-1209, SHR1209
Recaticimab (SHR-1209) 是一种人源化单克隆抗体,靶向 PCSK9。通过结合 PCSK9,Recaticimab 促进肝细胞 LDL 受体的稳定及表面表达,降低血浆 LDL 胆固醇水平。Recaticimab 正在作为高胆固醇血症及相关心血管疾病的化合物进行研究。

为众多的药物研发团队赋能,
让新药发现更简单!
Recaticimab (SHR-1209) 是一种人源化单克隆抗体,靶向 PCSK9。通过结合 PCSK9,Recaticimab 促进肝细胞 LDL 受体的稳定及表面表达,降低血浆 LDL 胆固醇水平。Recaticimab 正在作为高胆固醇血症及相关心血管疾病的化合物进行研究。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,730 | 现货 | |
| 5 mg | ¥ 4,260 | 现货 | |
| 10 mg | ¥ 5,920 | 现货 | |
| 25 mg | ¥ 8,830 | 现货 | |
| 50 mg | ¥ 11,800 | 现货 |
| 产品描述 | Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9. By binding to PCSK9, Recaticimab promotes LDL receptor stabilization and surface expression on hepatocytes, leading to reduced plasma LDL cholesterol levels. Recaticimab is under study as a therapeutic candidate for hypercholesterolemia and related cardiovascular disorders. |
| 别名 | 瑞卡西单抗, SHR-1209, SHR1209 |
| 反应种属 | Human |
| 应用 | ELISA FCM Functional assay |
| 抗体种类 | Monoclonal |
| 内毒素 | <1.0 EU/mg |
| 同型 | Human IgG1 kappa |
| 推荐同型对照 |
| 偶联 | Unconjugated |
| 基因ID | |
| Uniprot ID | |
| 靶点 | PCSK9 |
| 分子量 | 148.41 kDa |
| CAS No. | 2361290-85-7 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
对于不同动物的给药剂量换算,您也可以参考 更多